ChatAbout Prof. Dr. Reinhard E. Voll
- Prof. Dr. Reinhard E. Voll is a Rheumatologist with 27+ years of experience.
- He worked as the Board member for the Center for Chronic Immunodeficiency (CCI), University Medical Center Freiburg in 2010, and also headed the IZKF Young Investigator Group 2 at the University Hospital of the Friedrich-Alexander from 2003-2009.
- He completed his graduation from the University of Erlangen-Nuremberg in 1984 and later did his postdoctoral training, Max-Planck-Society, Clinical Research Units for Rheumatology at the University of Erlangen-Nürnberg, Germany.
- He has been awarded a postdoctoral fellowship of the DFG at Howard Hughes Medical Institute, Yale University, School of Medicine, New Haven, the USA in 1996.
- He has worked on several research projects and has nearly 200+ publications,
Hospital
Location
LocationFreiburg, Germany
Special Interest
Rheumatoid Arthritis Treatment Myositis IVIG Sarcoidosis Psoriasis Treatment Ankylosing Spondylitis Treatment Arthritis and Pain Management Scleroderma Treatment Autoimmune disorders Fibromyalgia Treatment Gout Treatment Systemic Sclerosis (Scleroderma) Arthritis Management
Work Experience of Prof. Dr. Reinhard E. Voll
Senior Consultant, University Hospital Erlangen
Prof. Dr. Reinhard E. Voll's
- Graduation, 1984, University of Erlangen-Nuremberg
- Fellowship, 1996, Yale University, School of Medicine, New Haven, CT, USA
- Alexander T, Sarfert R, Hiepe F, Voll RE. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis. 2015; 74(7):1474-8.
- Sehnert B, Burkhardt H, Wessels JT, Schröder A, May MJ, Vestweber D, Zwerina J, Warnatz K, Nimmerjahn F, Schett G, Dübel S, Voll RE. NF-κB inhibitor targeted to activated endothelium demonstrates a critical role of endothelial NF-κB in immune-mediated diseases. Proc Natl Acad Sci USA. 2013; 110(41):16556-16561.
- Fürnrohr BG, Wach S, Harley JB, Voll RE. Polymorphisms in the Hsp70 gene locus are genetically associated with systemic lupus erythematosus. Ann Rheum Dis. 2010; 69(11):1983-9.
- Urbonaviciute V, Fürnrohr BG, Herrmann M, Voll RE. Induction of infl ammatory and immune responses by HMGB1-nucleosome complexes – implications for the pathogenesis of SLE; J Exp Med. 2008; 205(13):3007-18.
- Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K, Wiethe C, Winkler TH, Kalden JR, Manz RA, Voll RE. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med. 2008; 14(7):748-55.
Wondering where to start?
(Get Free opinion, Quote, Medical Visa Invitation and Assistance at every step of your treatment.)
